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ABSTRACT
Background: No biomarker is available to predict prognosis of patients with 
advanced ovarian cancer (AOC) and guide the choice of chemotherapy. We performed 
a prospective-retrospective biomarker study within the MITO2 trial on the treatment 
of AOC. 
Patients and methods: MITO2 is a randomised multicentre phase 3 trial conducted 
with 820 AOC patients assigned carboplatin/paclitaxel (carboplatin: AUC5, paclitaxel: 
175 mg/m², every 3 weeks for 6 cycles) or carboplatin/PLD-pegylated liposomal 
doxorubicin (carboplatin: AUC5, PLD: 30 mg/m², every 3 weeks for 6 cycles) as 
first line treatment. Sixteen biomarkers (pathways of adhesion/invasion, apoptosis, 
transcription regulation, metabolism, and DNA repair) were studied in 229 patients, in 
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INTRODUCTION
Ovarian cancer includes a heterogeneous group of 
neoplasms, commonly classified according to clinical, 
morphological and molecular features. [1] Nevertheless, 
medical treatment of all types of epithelial ovarian cancer 
includes carboplatin/paclitaxel as standard backbone, 
also in combination with bevacizumab. [2-4] Therefore, 
biomarkers able to identify patients who may benefit from 
standard or alternative chemotherapy might be useful in 
clinical practice. 
The possibility of grouping ovarian cancer based 
on molecular portrait has been proposed, [5, 6] and 
biochemical and molecular markers have been studied as 
prognostic or predictive factors. [7-9] However, only few 
immunohistochemistry (IHC) studies have been conducted 
in large series, through consortia or as meta-analysis. [8, 
10, 11] Yet, with the exception of BRCA1/2 mutations 
to guide administration of PARP inhibitors, [12, 13] no 
biomarker is used in clinical practice. 
In 2011, with a 40 months median follow-up, 
the MITO2 trial showed that carboplatin/PLD was not 
superior to carboplatin/paclitaxel as first line treatment of 
ovarian cancer patients. [14] Here, with long-term follow 
up data, we tested the prognostic and/or predictive role of 
some biomarkers according to a prospective-retrospective 
design. [15] 
RESULTS
Long-term efficacy analysis in the whole study 
population
After 72 months median follow-up (interquartile 
range: 60-85), in the whole population of 820 patients, 
there were 594 events for PFS and 426 events for OS 
analysis. PFS HR for the carboplatin/PLD vs carboplatin/
paclitaxel arm was 0.99 (95%CI 0.84-1.17; p = 0.93); 
median PFS was 18 (95%CI 16-23) and 17 months 
(95%CI 15-19) in the two arms, respectively. OS HR for 
the carboplatin/PLD vs carboplatin/paclitaxel arm was 
0.94 (95%CI 0.77-1.13; p = 0.49); median OS was 61 
(95%CI 51-77) and 53 months (95%CI 42-70) in the two 
arms, respectively (Figure S1 online).
Biomarker analyses
Seventeen centres, enrolling 549 patients (67% 
of the whole study), supplied paraffin blocks from the 
primary tumor of 258 patients; 28 were excluded because 
tumor had been collected during interval debulking surgery 
after initiation of chemotherapy or date of collection was 
unknown. Therefore, 230 were eligible of whom 229 
(42% of patients enrolled in the centres participating to 
the biomarker study and 28% of the whole study) had at 
least one biomarker tested and represented the biomarker 
population (Figure S2 online). 
The biomarker population was similar to the overall 
study population, with a slightly lower rate of patients 
who were not operated at baseline and who had stage 
IV disease at diagnosis (Table S2 online). Consistently, 
both PFS and OS were slightly better in the biomarker 
population compared to the overall MITO2 population and 
to all patients enrolled in the centres participating to the 
biomarker study (Figure S3 online).
Distribution of biomarkers by treatment arm 
is reported in Table S3 online; due to core losses from 
the slides during IHC procedure, the number of cases 
tested ranged from 153 (pAMPK) to 223 (CDK6). No 
imbalances were observed between treatment arms at the 
planned significance level of 0.01.
Moderate pairwise associations (Table S4 online) 
were only found between pACC and either DNA-PK 
(Cramer’s V = 0.487, p < 0.001) or pAMPK (Cramer’s V 
= 0.433, p < 0.001). 
There were no statistically significant associations 
at the level of 0.001 between patients’ or tumors’ 
characteristics and biomarkers’ categories (Tables S5-S23 
online) except for DNA-PK and residual disease (Table 
S23 online). Univariate PFS and OS Kaplan-Meier curves 
for each biomarker are depicted in Figures S4-S41 online.
No biomarker had statistically significant 
(predefined significance level of 0.01) prognostic value 
for PFS and OS at multivariable analyses (Table 1). 
a tissue microarray. Progression-free and overall survival were analysed with multivariable 
Cox model. 
Results: After 72 months median follow-up, 594 progressions and 426 deaths were 
reported; there was no significant difference between the two arms in the whole trial. 
No biomarker had significant prognostic value. Statistically significant interactions with 
treatment were found for DNA-dependent protein kinase (DNA-PK) and phosphorylated 
acetyl-coenzymeA carboxylase (pACC), both predicting worse outcome for patients 
receiving carboplatin/paclitaxel. 
Conclusion: These data show that in presence of DNA-PK or pACC overexpression, 
carboplatin/paclitaxel might be less effective than carboplatin/PLD as first line treatment 
of ovarian cancer patients. Further validation of these findings is warranted.
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Figure 1: Kaplan-Meier estimated curves of progression-free survival (top) and overall survival (bottom) according 
to pACC status (negative: graphs on the left, positive: graphs on the right). Solid line: carboplatin/paclitaxel; dashed line: 
carboplatin/PLD. Vertical lines represent censoring.
Figure 2: Kaplan-Meier estimated curves of progression-free survival (top) and overall survival (bottom) according to 
DNA-PK status (negative/moderate: graphs on the left, high: graphs on the right). Solid line: carboplatin/paclitaxel; dashed 
line: carboplatin/PLD. Vertical lines represent censoring.
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At multivariable analyses of putative predictive 
biomarkers (Table 2), the predictive value role was 
confirmed for pACC (for both PFS and OS) and for 
DNA-PK (only for PFS). In both cases the presence of the 
biomarker appears to reduce the effect of the carboplatin/
paclitaxel combination (Figures 1 and 2). 
DISCUSSION
We tried to find out molecular tumor characteristics 
that may ultimately be useful for prognostic prevision and 
to guide the choice of chemotherapy, within the MITO-
2 randomized clinical trial of first-line chemotherapy for 
patients with AOC. None of 16 putative biomarkers had 
significant independent prognostic value; the expression 
of pACC and DNA-PK had a statistically significant 
interaction with treatment identifying patients who had 
less benefit from the carboplatin/paclitaxel combination 
as compared to the carboplatin/PLD one. 
A biomarker analysis performed within a prospective 
clinical trial, with a common protocol for archival tumor 
samples management and statistical analysis independent 
of the laboratories (reducing risk of ex-post hypotheses 
adjustment), has a level of evidence immediately behind 
that of trials prospectively planned for biomarker analysis. 
[15] Nevertheless, our study has a priori limitations. First, 
previous evidence had several weaknesses, deriving from 
small, retrospective, selected, non-protocol-driven data 
sets. Second, tumor collection was not mandatory in 
MITO2, and an attrition bias was expected, that further 
increased due to random missing data produced by 
technical limitations of TMA technology; therefore, our 
study is powered for medium-large prognostic effects. 
Third, a conservative statistical approach was required 
to reduce the risk of false positive results coming from 
multiple testing. 
Two biomarkers, DNA-PK and pACC, had a 
statistically significant interaction with treatment, their 
overexpression being predictive of worse efficacy of the 
carboplatin/paclitaxel treatment. This is consistent with the 
hypothesis that high DNA-PK expression should identify 
patients more resistant to paclitaxel therapy. [16] DNA-
PK and pACC expression have different functions, since 
DNA-PK is the catalytic subunit of a complex necessary 
for the Non-Homologous End Joining (NHEJ) DNA repair 
activity, [17] while ACC is the enzyme that converts 
acetyl-CoA in malonyl-CoA; the latter is phosphorylated 
and inhibited by AMP-activated protein kinase (AMPK), 
Table 1: Summary of multivariable analyses with candidate prognostic biomarkers
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Figure 3: Possible molecular links between DNA-PKs and pACC expression. A. DNA-PK could phosphorylate and activate 
AMPK directly, or indirectly via LKB1. AMPK activation eventually results in high ACC phosphorylation. B. DNA-PK phosphorylates the 
transcription factor USF1. This event is necessary for the proper expression of FAS (and ACC) by SREBP-1. Higher levels of pACC are in 
this case the consequence of higher levels of the total protein.
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a sensor of cellular energy charge and a metabolic master 
switch. [18] In the present study, DNA-PK and pACC 
expression were correlated (Cramer’s V = 0.487, p < 
0.001) and there are at least two likely explanations for this 
correlation (Figure 3). First, DNA-PK could activate both 
LKB1 and AMPK, resulting in high ACC phosphorylation. 
[17, 19] Second, DNA-PK is a master regulator of fatty 
acids synthesis and its expression and activity is necessary 
for the proper regulation of the transcription factors USF1 
and SERBP1 that control the expression of ACC and FAS 
(Fatty Acid Synthase). [20] In any case, it is now clear 
that DNA-PK is necessary for several biological functions 
other than the control of NHEJ DNA-repair and, among 
these, regulation of cellular metabolism via transcription 
regulation seems to be of primary relevance. [17, 21] 
AMPK also plays an important role in this setting; its 
activation, indeed, is necessary for the proper induction of 
doxorubicin-mediated death in several models, possibly 
through the control of autophagy; [22, 23] on the contrary, 
the same mechanism has been shown to protect cells from 
paclitaxel induced cell death, enhancing glycolysis during 
mitosis and preventing mitotic cell death. [24] These 
data strongly suggest that higher DNA-PK expression 
can prompt higher AMPK activity, causing higher 
pACC levels, and ultimately identifies ovarian cancer 
cells resistant to paclitaxel and sensitive to doxorubicin 
treatment.
Alternatively, it should be considered that paclitaxel 
action on interphase microtubules alters proteins transport 
and re-localization and may prevent nuclear localization 
of the enzymes involved in DNA-repair activity including 
DNA-PK, potentiating the activity of cytotoxic drug 
like platinum. [25-27] It is therefore possible that cells 
expressing high levels of DNA-PK are less sensitive to 
paclitaxel-induced DNA-PK cytoplasmic retention and 
more resistant to the effect of the carboplatin/paclitaxel 
combination. 
In conclusion, we believe that our findings unveil 
a new pathway in ovarian cancer that might play an 
important role in the response of therapy. Additional work 
is needed to substantiate this hypothesis and to definitely 
clarify the involved mechanisms; also, further validation 
in larger series or prospective trials is warranted. DNA-
PK and pACC might be first-in-kind biomarkers for 
personalizing the choice of chemotherapy regimen in 
ovarian cancer.
MATERIALS AND METHODS
MITO2 is registered at clinicaltrials.gov 
NCT00326456. Trial details have been previously 
reported. [14] In the present long-term efficacy analysis, 
PFS and OS curves were reported according to the Kaplan-
Meier method and were compared with the Log-rank test. 
Median estimates and HR, with 95% confidence intervals 
(CI) were also reported. All the analyses were performed 
according to intention-to-treat.
Following the approval of study amendments 
by Ethical Committee and patients’ consent, tissue 
microarrays (TMA), prepared at the Pathology Unit 
of the NCI Naples (see page 5 online), were sent to 
seven laboratories involved in the study to test 16 
putative biomarkers, some of which had more than one 
measurement, leading to 19 analyses. Biomarkers were 
classified according to their prevalent biological activity 
in 5 different groups: adhesion/invasion, apoptosis, 
transcription regulation, metabolism, DNA repair. 
Expected/hypothesized role and evidence or preliminary 
data for each studied biomarker are detailed online (pages 
5-10 online). Methods for biomarker testing procedures 
are detailed in Table S1 online. Investigators involved 
in TMA preparation and analysis were blinded to the 
assigned treatment and patients’ outcome.
The biomarker population was defined as the 
subgroup of patients for whom at least one biomarker 
result was available. Different two-tailed significance 
levels were applied to different biomarker analyses to 
Table 2: Summary of multivariable analyses with candidate prognostic and predictive biomarkers
Oncotarget7www.impactjournals.com/oncotarget
partially adjust for multiple comparisons. Three planned 
conventional levels of P value, more or less conservative, 
were used according to the specific aim and the number of 
planned tests (0.001, 0.01, 0.05).
Baseline characteristics, and PFS and OS outcomes 
of the biomarker population were described, without 
statistical testing, to allow an informal comparison with 
the whole study population and the population of patients 
enrolled by the centres that participated in tumor block 
collection. 
Association of biomarkers with baseline 
characteristics of the patients and the tumors were 
described and tested with the Chi-square test or the 
Wilcoxon rank sum test or the Kruskal-Wallis test, as 
appropriate, using a significance level of 0.001. PFS and 
OS curves were drawn with the Kaplan-Meier method.
Biomarkers were categorized in two or more levels 
according to predefined cut-offs. Pairwise associations 
between biomarkers were assessed by means of Cramer’s 
V ranging from 0 (no association ) to 1 (two variables 
fully concordant, give the same information). Statistical 
significance of pairwise associations was assessed with 
Chi-square test, using a significance level of 0.001. 
The analysis of the prognostic role of each 
biomarker was adjusted by predefined clinical prognostic 
factors. Endpoints were PFS and OS. Each biomarker was 
added to a multivariable Cox’s model with treatment arm, 
stage, residual disease, grading and age as covariates and 
prognostic effect was tested at a significance level of 0.01. 
For P53, pAMPK, pACC, Stathmin, and DNA-
PK previous data suggested a modifying effect on the 
treatment with taxane/anthracycline (see appendix 
online). Therefore, a predictive role had to be assessed 
and it was planned a priori to test the biomarker*treatment 
interaction, using the conventional significance level of 
0.05. If the interaction test was not statistically significant 
the prognostic effect was evaluated as above.
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